Reliever effect of extrafine BDP/F DPI in asthmatic patients after methacholine challenge

M. Corradi (Parma, Italy), D. Singh (Manchester, United Kingdom), F. Van Den Berg (London, United Kingdom), B. Leaker (London , United Kingdom), S. Jabbal (Dundee, United Kingdom), S. Collarini (Parma, Italy), V. Mongelli (Parma, Italy), L. Santoro (Parma, Italy), A. Piccinno (Parma, Italy), S. Biondaro (Parma, Italy), B. Lipworth (Dundee, United Kingdom)

Source: International Congress 2018 – New developments in the treatment of asthma
Session: New developments in the treatment of asthma
Session type: Thematic Poster
Number: 1039
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Corradi (Parma, Italy), D. Singh (Manchester, United Kingdom), F. Van Den Berg (London, United Kingdom), B. Leaker (London , United Kingdom), S. Jabbal (Dundee, United Kingdom), S. Collarini (Parma, Italy), V. Mongelli (Parma, Italy), L. Santoro (Parma, Italy), A. Piccinno (Parma, Italy), S. Biondaro (Parma, Italy), B. Lipworth (Dundee, United Kingdom). Reliever effect of extrafine BDP/F DPI in asthmatic patients after methacholine challenge. 1039

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
HFA beclomethasone dipropionate (HFA-BDP) extrafine aerosol and formoterol in optimizing the management of bronchial asthma at children
Source: Eur Respir J 2005; 26: Suppl. 49, 159s
Year: 2005

Protection against methacholine-induced bronchospasm: salbutamol pMDI versus Clickhaler(R) DPI
Source: Eur Respir J 2003; 21: 816-820
Year: 2003



The anti-inflammatory effect of budesonide 800 μg/day via Easyhaler® compared with the same dose of budesonide via Turbuhaler® in adult asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 337s
Year: 2001

Maintenance of lung function and asthma control with extrafine beclomethasone/formoterol
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

Same minimal effective dose of budesonide Turbuhaler® and fluticasone Diskus®/Accuhaler® in adult asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 158s
Year: 2001

The effects of extrafine beclomethasone/formoterol on hyperinflation and airway geometry in COPD patients
Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD
Year: 2012


Effect of montelukast or salmeterol added to inhaled fluticasone on response to albuterol in children with exercise-induced bronchoconstriction
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009

Comparison of the bronchoprotective effects of two salbutamol suplphate HFA pMDI using methacholine challenge testing
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Efficacy of salmeterol/fluticasone pMDI versus DPI in patients with asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 499s
Year: 2006

Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone
Source: Eur Respir J 2001; 18: 262-268
Year: 2001



Comparison of a new extrafine beclomethasone dipropionate HFA134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 206s
Year: 2006

QVAR pMDI is more cost effective than CFC-beclometasone dipropionate (BDP) pMDI in a real-life asthmatic population initiating ICS
Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care
Year: 2009

The novel budesonide HFA pMDI is clinically comparable to the conventional budesonide CFC pMDI in paediatric patients with asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 160s
Year: 2005

Cost-effectiveness of budesonide and formoterol in a single inhaler compared to fluticasone in the treatment of asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 157s
Year: 2001

Bronchoprotective and anti-inflammatory effect of beclometasone dipropionate plus formoterol HFA fixed combination in asthmatic patients
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009

Device preference and efficacy of formoterol aerolizer and salbutamol MDI in children with asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 134s
Year: 2003

Comparison of two budesonide powder inhalers, Giona Easyhaler® and Pulmicort Turbuhaler® in steroid-naive asthmatic patients
Source: Eur Respir J 2001; 18: Suppl. 33, 100s
Year: 2001

Non-inferiority comparison of budesonide HFA (BUD-HFA) pMDI with budesonide CFC (BUD-CFC) pMDI in patients with persistent moderate asthma
Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care
Year: 2008


Budesonide and formoterol in a single inhaler quickly gains asthma control compared with fluticasone propionate in mild asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 48s
Year: 2001

Protective effect of inhaled beclomethasone dipropionate (BDP) in asthmatic patients with exercise-induced bronchoconstriction (EIB)
Source: Eur Respir J 2002; 20: Suppl. 38, 306s
Year: 2002